Therapeutic RNA manipulation in liver disease

Hepatology

Volumn 51, Issue 3, 2010, Pages 1055-1061

  Kerr, Thomas A ^a   Davidson, Nicholas O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGODEOXYNUCLEOTIDE; FOMIVIRSEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MESSENGER RNA; MICRORNA; MIPOMERSEN; PLACEBO; RIBOZYME; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; DRUG EFFECT; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC DISORDER; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSTIMULATION; INJECTION SITE ERYTHEMA; LIVER DISEASE; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; RIBOZYME THERAPY; RNA DEGRADATION; RNA INTERFERENCE; RNA METABOLISM; RNA SPLICING; RNA SYNTHESIS; TREATMENT DURATION; TREATMENT INDICATION;

GENE THERAPY; HUMANS; LIVER DISEASES; RNA; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 77950601100     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23344     Document Type: Review

References (70)

1. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell 2009;136:777-793.
2. Matlin AJ, Clark F, Smith CW. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 2005;6:386-398.
3. Erkmann JA, Kutay U. Nuclear export of mRNA: from the site of transcription to the cytoplasm. Exp Cell Res 2004;296:12-20.
4. Sonenberg N. eIF4E, the mRNA cap-binding protein: from basic discovery to translational research. Biochem Cell Biol 2008;86:178-183.
5. Bi X, Goss DJ. Wheat germ poly(A)-binding protein increases the ATPase and the RNA helicase activity of translation initiation factors eIF4A, eIF4B, and eIF-iso4F. J Biol Chem 2000;275:17740-17746.
6. Goldstrohm AC, Wickens M. Multifunctional deadenylase complexes diversify mRNA control. Nat Rev Mol Cell Biol 2008;9:337-344.
7. Hodgman R, Tay J, Mendez R, Richter JD. CPEB phosphorylation and cytoplasmic polyadenylation are catalyzed by the kinase IAK1/Eg2 in maturing mouse oocytes. Development 2001;128:2815-2822.
8. Beilharz TH, Preiss T. Widespread use of poly(A) tail length control to accentuate expression of the yeast transcriptome. RNA 2007;13:982-997.
9. Hilgers V, Teixeira D, Parker R. Translation-independent inhibition of mRNA deadenylation during stress in Saccharomyces cerevisiae. RNA 2006;12:1835-1845.
10. Kedersha N, Stoecklin G, Ayodele M, Yacono P, Lykke-Andersen J, Frit-zler MJ, et al. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol 2005;169:871-884.
11. Garneau NL, Wilusz J, Wilusz CJ. The highways and byways of mRNA decay. Nat Rev Mol Cell Biol 2007;8:113-126.
12. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995;20:465-470.
13. Anant S, Murmu N, Houchen CW, Mukhopadhyay D, Riehl TE, Young SG, et al. Apobec-1 protects intestine from radiation injury through post-transcriptional regulation of cyclooxygenase-2 expression. Gastroenterol-ogy 2004;127:1139-1149.
14. Anant S, Houchen CW. HuR and TTP: two RNA binding proteins that deliver message from the 3' end. Gastroenterology 2009;136:1495-1498.
15. Moraes KC, Wilusz CJ, Wilusz J. CUG-BP binds to RNA substrates and recruits PARN deadenylase. RNA 2006;12:1084-1091.
16. Lee HK, Jeong S. Beta-Catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR. Nucleic Acids Res 2006;34: 5705-5714.
17. Briata P, Forcales SV, Ponassi M, Corte G, Chen CY, Karin M, et al. p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell 2005; 20:891-903.
18. O'Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF. MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology 2009;136:17-25.
19. Wu L, Belasco JG. Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs. Mol Cell 2008;29:1-7.
20. Behm-Ansmant I, Rehwinkel J, Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol 2006;71:523-530.
21. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
22. Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol 2009;10:141-148.
23. Chen X. A microRNA as a translational repressor of APETALA2 in Ara-bidopsis flower development. Science 2004;303:2022-2025. (Pubitemid 38393278)
24. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006;125:1111-1124.
25. Stephenson ML, Zamecnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 1978;75:285-288.
26. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75:280-284.
27. Wu H, Lima WF, Zhang H, Fan A, Sun H, Crooke ST. Determination of the role of the human RNase H1 in the pharmacology of DNA-like anti-sense drugs. J Biol Chem 2004;279:17181-17189.
28. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 2003;21:1457-1465.
29. Wood M, Yin H, McClorey G. Modulating the expression of disease genes with RNA-based therapy. PLoS Genet 2007;3:e109.
30. Koziolkiewicz M, GendaszewskaE, Maszewska M,Stein CA, Stec WJ. The mononucleotide-dependent, nonantisense mechanism of action of phos-phodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase. Blood 2001;98:995-1002.
31. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1:347-355.
32. Bonetta L. RNA-based therapeutics: ready for delivery? Cell 2009;136: 581-584.
33. Lacerra G, Sierakowska H, Carestia C, Fucharoen S, Summerton J, Weller D, et al. Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci USA 2000; 97:9591-9596.
34. Loudianos G, Lovicu M, Dessi V, Tzetis M, Kanavakis E, Zancan L, et al. Abnormal mRNA splicing resulting from consensus sequence splicing mutations of ATP7B. Hum Mutat 2002;20:260-266.
35. Sze KM, Ching YP, Jin DY, NgIO. Role of a novel splice variant of mitotic arrest deficient 1 (MAD1), MAD1beta, in mitotic checkpoint control in liver cancer. Cancer Res 2008;68:9194-9201.
36. Ma ZM, Lin X, Wang YX, Tian XC, Xie YH, Wen YM. A double-spliced defective hepatitis B virus genome derived from hepatocellular carcinoma tissue enhanced replication of full-length virus. J Med Virol 2009;81:230-237.
37. Khoo B, Krainer AR. Splicing therapeutics in SMN2 and APOB. Curr Opin Mol Ther 2009;11:108-115.
38. Khoo B, Roca X, Chew SL, Krainer AR. Antisense oligonucleotide-in-duced alternative splicing of the APOB mRNA generates a novel isoform of APOB. BMC Mol Biol 2007;8:3.
39. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001;98:42-47.
40. Lan N, Howrey RP, Lee SW, Smith CA, Sullenger BA. Ribozyme-medi-ated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science 1998;280:1593-1596.
41. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol 2005;3:e85.
42. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 2007;59:75-86.
43. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-541.
44. John M, Constien R, Akinc A, Goldberg M, Moon YA, Spranger M, et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 2007;449:745-747.
45. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438: 685-689.
46. Soni PN, Brown D, Saffie R, Savage K, Moore D, Gregoriadis G, et al. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. HEPATOLOGY 1998;28: 1402-1410.
47. Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18:862-867.
48. Kawakami S, Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007;22: 142-151.
49. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004;14:1139-1143.
50. Corey DR. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007;117:3615-3622.
51. Frank-Kamenetsky M, Grefhorst A, Anderson NN, Racie TS, Bramlage B, Akinc A, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008;105:11915-11920.
52. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-178.
53. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-114.
54. De Paula D, Bentley MV, Mahato RI. Hydrophobization and bioconju-gation for enhanced siRNA delivery and targeting. RNA 2007;13:431-456.
55. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13:494-505.
56. Benimetskaya L, Takle GB, Vilenchik M, Lebedeva I, Miller P, Stein CA. Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucle- otides. Nucleic Acids Res 1998;26:5310-5317.
57. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Bio-technol 2003;21:635-637.
58. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-563.
59. Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005; 46:872-884.
60. Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-1735.
61. Genzyme. Genzyme and Isis announce that Mipomersen phase 3 study in patients with homozygous familial hypercholesterolemia met primary end-point. Available at: http://www.genzyme.com/corp/media/genz%20PR-052009.asp. Accessed July 5, 2009.
62. Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci 2005;62:1372-1378.
63. Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res 2003;44:878-883.
64. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007;32:71-77.
65. Rashid S, Curtis DE, Garuti R, Anderson NN, BashmakovY,Ho YK, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005;102:5374-5379.
66. CohenJ, PertsemlidisA,Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161-165.
67. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007;48:763-767.
68. Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. HEPATOLOGY 2008;48:1810-1820.
69. Elmen J, Lindow M, Silahtaroglu A, Bak M, Christensen M, Lind-Thom-sen A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008;36:1153-1162.
70. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9:347-351.